ArticleJournal of diabetes investigation2025
YY2 mediates transcriptional repression of PHGDH and expedites oxidative stress in retinal pigment epithelial cells in diabetic retinopathy.
Article in Journal of diabetes investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Mechanistic insights into SOCS5-related DNA damage and cellular senescence in diabetic retinopathy.Cell death discovery · 2026Article
- Metabolic reprogramming in diabetic complications: mechanisms, pathologies, and molecular evidence from multi-organ studies.Frontiers in immunology · 2026Review
- Ferroptosis in diabetic retinopathy: from pathogenic mechanisms to translational prospects.Frontiers in endocrinology · 2026Review
- Protein post-translational modifications in serine synthetic pathway: functions and molecular mechanisms.Cell communication and signaling : CCS · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
AIMS/
introductionPhosphoglycerate dehydrogenase (PHGDH), which controls serine synthesis, has been linked to retinal disease. However, there are no clues about its involvement in the diabetic retinopathy (DR) progression. Therefore, we aimed to investigate the relationship between PHGDH, serine synthesis, and DR and their underlying molecular mechanisms.
methodDifferentially expressed genes in DR were screened using bioinformatics tools. DR mice were induced, and retinal histopathology was observed in mice. Overexpression of PHGDH was induced in the DR mice to measure l-serine, ROS, and MDA content in the retinas of DR mice. ARPE-19 cells were transfected with overexpression of PHGDH and exposed to high glucose to induce a DR in vitro model, and cell viability and apoptosis assays, serine content, and oxidative stress factor measurement were conducted. The transcriptional regulation of PHGDH by YY2 was explored by ChIP and dual-luciferase reporter assays. Finally, the combined role of YY2 and PHGDH in regulating serine synthesis, oxidative stress, and ferroptosis was investigated.
resultsPHGDH expression was reduced in DR mice, and overexpression of PHGDH alleviated DR progression by promoting serine synthesis and attenuating oxidative stress. YY2 bound to the promoter of PHGDH and mediated its transcriptional repression. YY2-mediated transcriptional repression of PHGDH caused disturbances in serine synthesis, leading to oxidative stress-triggered ferroptosis.
conclusionsOur data prove that YY2 plays a vital role in modulating PHGDH expression, impairing serine synthesis, and expediting oxidative stress and ferroptosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.